Relapses (episodic exacerbations of neurological signs or symptoms) are a defining feature of relapsing-remitting multiple sclerosis (MS), the most prevalent MS phenotype. While their diagnostic value relates predominantly to the definition of clinically definite MS, their prognostic value is determined by their relatively high associated risk of incomplete remission resulting in residual disability. The mechanisms governing a relapse incidence are unknown, but numerous modifiers of relapse risk have been described, including demographic and clinical characteristics, many of which represent opportunities for improved disease management. Also relapse phenotypes have been associated with patient and disease characteristics and an individual predisposition to certain phenotypic presentations may imply individual neuroanatomical disease patterns. While immunomodulatory therapies and corticosteroids represent the mainstay of relapse prevention and acute management, respectively, their effect has only been partial and further search for more efficient relapse therapies is warranted. Other areas of research include pathophysiology and determinants of relapse incidence, recurrence and phenotypes, including the characteristics of the relapsing and non-relapsing multiple sclerosis variants and their responsiveness to therapies.

Keywords:
Multiple sclerosis, Relapse, Therapy, Phenotype, Recurrence, Disease outcomes, Steroids, MRI, Registry, Geography
1.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
2.
Raimundo K, Tian H, Zhou H, Zhang X, Kahler KH, Agashivala N, Kim E: Resource utilization, costs and treatment patterns of switching and discontinuing treatment of ms patients with high relapse activity. BMC Health Serv Res 2013;13:131.
3.
Blahova Dusankova J, Kalincik T, Dolezal T, Kobelt G, Havrdova E: Cost of multiple sclerosis in the Czech Republic: the COMS study. Mult Scler 2012;18:662-668.
4.
O'Brien JA, Ward AJ, Patrick AR, Caro J: Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003;3:17.
5.
Kobelt G, Berg J, Lindgren P, Fredrikson S, Jönsson B: Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006;77:918-926.
6.
Steinman L: Immunology of relapse and remission in multiple sclerosis. Annu Rev Immunol 2014;32:257-281.
7.
Barnett MH, Henderson AP, Prineas JW: The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion. Mult Scler 2006;12:121-132.
8.
Smith KJ, McDonald WI: The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci 1999;354:1649-1673.
9.
Brinkmeier H, Seewald MJ, Wollinsky KH, Rüdel R: On the nature of endogenous antiexcitatory factors in the cerebrospinal fluid of patients with demyelinating neurological disease. Muscle Nerve 1996;19:54-62.
10.
Redford EJ, Kapoor R, Smith KJ: Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 1997;120:2149-2157.
11.
Schauf CL, Davis FA: The occurrence, specificity, and role of neuroelectric blocking factors in multiple sclerosis. Neurology 1978;28:34-39.
12.
Takigawa T, Yasuda H, Kikkawa R, Shigeta Y, Saida T, Kitasato H: Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers. Ann Neurol 1995;37:436-442.
13.
Bolaños JP, Almeida A, Stewart V, Peuchen S, Land JM, Clark JB, Heales SJ: Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. J Neurochem 1997;68:2227-2240.
14.
Yu B, Shinnick-Gallagher P: Interleukin-1 beta inhibits synaptic transmission and induces membrane hyperpolarization in amygdala neurons. J Pharmacol Exp Ther 1994;271:590-600.
15.
Wiebe S, Lee DH, Karlik SJ, Hopkins M, Vandervoort MK, Wong CJ, Hewitt L, Rice GP, Ebers GC, Noseworthy JH: Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis. Ann Neurol 1992;32:643-650.
16.
Gasperini C, Pozzilli C, Bastianello S, Koudriavtseva T, Colleluori A, Millefiorini E, Thompson AJ, Horsfield MA, Galgani S, Bozzao L, Fieschi C: The influence of clinical relapses and steroid therapy on the development of Gd-enhancing lesions: a longitudinal MRI study in relapsing-remitting multiple sclerosis patients. Acta Neurol Scand 1997;95:201-207.
17.
Davis FA: The clinico-radiological paradox in multiple sclerosis: novel implications of lesion size. Mult Scler 2014;20:515-516.
18.
Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, Salanti G: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev 2013;6:CD008933.
19.
Hutchinson M: Relapses do not matter in relation to long-term disability: commentary. Mult Scler 2011;17:1417.
20.
Inusah S, Sormani MP, Cofield SS, Aban IB, Musani SK, Srinivasasainagendra V, Cutter GR: Assessing changes in relapse rates in multiple sclerosis. Mult Scler 2010;16:1414-1421.
21.
Steinvorth SM, Rover C, Schneider S, Nicholas R, Straube S, Friede T: Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression. Mult Scler 2013;19:1580-1586.
22.
Sormani MP, Tintorè M, Rovaris M, Rovira A, Vidal X, Bruzzi P, Filippi M, Montalban X: Will Rogers phenomenon in multiple sclerosis. Ann Neurol 2008;64:428-433.
23.
Sormani MP, Signori A, Siri P, De Stefano N: Time to first relapse as an endpoint in multiple sclerosis clinical trials. Mult Scler 2013;19:466-474.
24.
Jin Y, de Pedro-Cuesta J, Söderström M, Stawiarz L, Link H: Seasonal patterns in optic neuritis and multiple sclerosis: a meta-analysis. J Neurol Sci 2000;181:56-64.
25.
Spelman T, Gray O, Trojano M, Petersen T, Izquierdo G, Lugaresi A, Hupperts R, Bergamaschi R, Duquette P, Grammond P, Giuliani G, Boz C, Verheul F, Oreja-Guevara C, Barnett M, Grand'Maison F, Edite Rio M, Lechner-Scott J, Van Pesch V, Fernandez Bolanos R, Flechter S, Den Braber-Moerland L, Iuliano G, Amato MP, Slee M, Cristiano E, Saladino ML, Paine M, Vella N, Kasa K, Deri N, Herbert J, Moore F, Petkovska-Boskova T, Alroughani R, Savino A, Shaw C, Vucic S, Santiago V, Bacile EA, Skromne E, Poehlau D, Cabrera-Gomez JA, Lucas R, Butzkueven H: Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. Ann Neurol 2014;76:880-890.
26.
Salvi F, Bartolomei I, Smolensky MH, Lorusso A, Barbarossa E, Malagoni AM, Zamboni P, Manfredini R: A seasonal periodicity in relapses of multiple sclerosis? A single-center, population-based, preliminary study conducted in Bologna, Italy. BMC Neurol 2010;10:105.
27.
Bamford CR, Sibley WA, Thies C: Seasonal variation of multiple sclerosis exacerbations in Arizona. Neurology 1983;33:697-701.
28.
Goodkin DE, Hertsgaard D: Seasonal variation of multiple sclerosis exacerbations in North Dakota. Arch Neurol 1989;46:1015-1018.
29.
Iuliano G, Boz C, Cristiano E, Duquette P, Lugaresi A, Oreja-Guevara C, Van Pesch V: Historical changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicenter study. J Neurol 2013;260:1258-1262.
30.
Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R: Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008;14:1220-1224.
31.
Runia TF, Hop WC, de Rijke YB, Buljevac D, Hintzen RQ: Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 2012;79:261-266.
32.
Kampman MT, Brustad M: Vitamin D: a candidate for the environmental effect in multiple sclerosis - observations from Norway. Neuroepidemiology 2008;30:140-146.
33.
Martinelli V, Dalla Costa G, Colombo B, Dalla Libera D, Rubinacci A, Filippi M, Furlan R, Comi G: Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler 2014;20:147-155.
34.
Simpson S Jr, Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H, Dwyer T, Gies P, van der Mei I: Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010;68:193-203.
35.
Mowry EM, Krupp LB, Milazzo M, Chabas D, Strober JB, Belman AL, McDonald JC, Oksenberg JR, Bacchetti P, Waubant E: Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010;67:618-624.
36.
Mowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR, Gourraud PA, Brenneman D, Owen MC, Qualley P, Bucci M, Hauser SL, Pelletier D: Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012;72:234-240.
37.
Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Radü EW, Sandbrink R, Kappos L, Pohl C: Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 2014;71:306-314.
38.
Goldberg P, Fleming MC, Picard EH: Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses 1986;21:193-200.
39.
Pierrot-Deseilligny C, Rivaud-Péchoux S, Clerson P, de Paz R, Souberbielle JC: Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation. Ther Adv Neurol Disord 2012;5:187-198.
40.
Bhargava P, Cassard S, Steele SU, Azevedo C, Pelletier D, Sugar EA, Waubant E, Mowry EM: The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. Contemp Clin Trials 2014;39:288-293.
41.
Smolders J, Hupperts R, Barkhof F, Grimaldi LM, Holmoy T, Killestein J, Rieckmann P, Schluep M, Vieth R, Hostalek U, Ghazi-Visser L, Beelke M; SOLAR Study Group: Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase ii, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci 2011;311:44-49.
42.
Kalincik T, Vivek V, Jokubaitis V, Lechner-Scott J, Trojano M, Izquierdo G, Lugaresi A, Grand'maison F, Hupperts R, Oreja-Guevara C, Bergamaschi R, Iuliano G, Alroughani R, Van Pesch V, Amato MP, Slee M, Verheul F, Fernandez-Bolanos R, Fiol M, Spitaleri DL, Cristiano E, Gray O, Cabrera-Gomez JA, Shaygannejad V, Herbert J, Vucic S, Needham M, Petkovska-Boskova T, Sirbu CA, Duquette P, Girard M, Grammond P, Boz C, Giuliani G, Rio ME, Barnett M, Flechter S, Moore F, Singhal B, Bacile EA, Saladino ML, Shaw C, Skromne E, Poehlau D, Vella N, Spelman T, Liew D, Kilpatrick TJ, Butzkueven H; MSBase Study Group: Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain 2013;136:3609-3617.
43.
Dobson R, Ramagopalan S, Giovannoni G: The effect of gender in clinically isolated syndrome (CIS): a meta-analysis. Mult Scler 2012;18:600-604.
44.
Tremlett H, Zhao Y, Joseph J, Devonshire V; UBCMS Clinic Neurologists: Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry 2008;79:1368-1374.
45.
Mowry EM, Pesic M, Grimes B, Deen SR, Bacchetti P, Waubant E: Clinical predictors of early second event in patients with clinically isolated syndrome. J Neurol 2009;256:1061-1066.
46.
Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T: Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 2009;66:54-59.
47.
Held U, Heigenhauser L, Shang C, Kappos L, Polman C; Sylvia Lawry Centre for MS Research: Predictors of relapse rate in MS clinical trials. Neurology 2005;65:1769-1773.
48.
West T, Wyatt M, High A, Bostrom A, Waubant E: Are initial demyelinating event recovery and time to second event under differential control? Neurology 2006;67:809-813.
49.
Kelly MA, Cavan DA, Penny MA, Mijovic CH, Jenkins D, Morrissey S, Miller DH, Barnett AH, Francis DA: The influence of HLA-DR and -DQ alleles on progression to multiple sclerosis following a clinically isolated syndrome. Hum Immunol 1993;37:185-191.
50.
Mowry EM, Carey RF, Blasco MR, Pelletier J, Duquette P, Villoslada P, Malikova I, Roger E, Kinkel RP, McDonald J, Bacchetti P, Waubant E: Multiple sclerosis susceptibility genes: associations with relapse severity and recovery. PLoS One 2013;8:e75416.
51.
Kalincik T, Guttmann CR, Krasensky J, Vaneckova M, Lelkova P, Tyblova M, Seidl Z, De Jager PL, Havrdova E, Horakova D: Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome. Genes Immun 2013;14:244-248.
52.
Jensen CJ, Stankovich J, Van der Walt A, Bahlo M, Taylor BV, van der Mei IA, Foote SJ, Kilpatrick TJ, Johnson LJ, Wilkins E, Field J, Danoy P, Brown MA, Rubio JP, Butzkueven H; Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene): Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients. PLoS One 2010;5:e10003.
53.
Lin R, Taylor BV, Simpson S Jr, Charlesworth J, Ponsonby AL, Pittas F, Dwyer T, van der Mei I: Association between multiple sclerosis risk-associated SNPs and relapse and disability - a prospective cohort study. Mult Scler 2014;20:313-321.
54.
Masterman T, Ligers A, Olsson T, Andersson M, Olerup O, Hillert J: HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 2000;48:211-219.
55.
Celius EG, Harbo HF, Egeland T, Vartdal F, Vandvik B, Spurkiand A: Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci 2000;178:132-135.
56.
Hensiek AE, Sawcer SJ, Feakes R, Deans J, Mander A, Akesson E, Roxburgh R, Coraddu F, Smith S, Compston DA: HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;72:184-187.
57.
Weinshenker BG, Santrach P, Bissonet AS, McDonnell SK, Schaid D, Moore SB, Rodriguez M: Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. Neurology 1998;51:742-747.
58.
Pittas F, Ponsonby AL, van der Mei IA, Taylor BV, Blizzard L, Groom P, Ukoumunne OC, Dwyer T: Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. J Neurol 2009;256:577-585.
59.
Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick J, Meier UC, Marta M, Costa GD, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Direnzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D'Alfonso S, Alvarez-Cermeño J, Kleinová P, Horáková D, Roesler R, Lauda F, Llufriu S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson H, Malmestrom C, Scarpini E, Fenoglio C, Wergeland S, Laroni A, Annibali V, Romano S, Martínez A, Carra A, Salvetti M, Uccelli A, Torkildsen Ø, Myhr K, Galimberti D, Rejdak K, Lycke J, Frederiksen J, Drulovic J, Confavreux C, Brassat D, Enzinger C, Fuchs S, Bosca I, Pelletier J, Picard C, Colombo E, Franciotta D, Derfuss T, Lindberg R, Yaldizli Ö, Vécsei L, Kieseier B, Hartung H, Villoslada P, Siva A, Saiz A, Tumani H, Havrdova E, Villar L, Leone M, Barizzone N, Deisenhammer F, Teunissen C, Montalban X, Tintoré M, Olsson T, Trojano M, Lehmann S, Castelnovo G, Lapin S, Hintzen R, Kappos L, Furlan R, Martinelli V, Comi G, Ramagopalan S, Giovannoni G: Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Mult Scler 2015;pii:1352458514568827.
60.
Mohr DC, Hart SL, Julian L, Cox D, Pelletier D: Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ 2004;328:731.
61.
Nisipeanu P, Korczyn AD: Psychological stress as risk factor for exacerbations in multiple sclerosis. Neurology 1993;43:1311-1312.
62.
Golan D, Somer E, Dishon S, Cuzin-Disegni L, Miller A: Impact of exposure to war stress on exacerbations of multiple sclerosis. Ann Neurol 2008;64:143-148.
63.
Kurland LT: Trauma and multiple sclerosis. Ann Neurol 1994;36(suppl):S33-S37.
64.
Artemiadis AK, Anagnostouli MC, Alexopoulos EC: Stress as a risk factor for multiple sclerosis onset or relapse: a systematic review. Neuroepidemiology 2011;36:109-120.
65.
Confavreux C, Suissa S, Saddier P, Bourdès V, Vukusic S; Vaccines in Multiple Sclerosis Study Group: Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in multiple sclerosis study group. N Engl J Med 2001;344:319-326.
66.
Mikaeloff Y, Caridade G, Assi S, Tardieu M, Suissa S; KIDSEP study group of the French Neuropaediatric Society: Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination. Brain 2007;130:1105-1110.
67.
Bamford CR, Sibley WA, Laguna JF: Swine influenza vaccination in patients with multiple sclerosis. Arch Neurol 1978;35:242-243.
68.
Myers LW, Ellison GW, Lucia M, Novom S, Holevoet M, Madden D, Sever J, Noble GR: Swine influenza virus vaccination in patients with multiple sclerosis. J Infect Dis 1977;136(suppl):S546-S554.
69.
Farez MF, Correale J: Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol 2011;68:1267-1271.
70.
Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF, van Der Meché FG, van Doorn PA, Hintzen RQ: Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002;125:952-960.
71.
Buljevac D, Verkooyen RP, Jacobs BC, Hop W, van der Zwaan LA, van Doorn PA, Hintzen RQ: Chlamydia pneumoniae and the risk for exacerbation in multiple sclerosis patients. Ann Neurol 2003;54:828-831.
72.
Edwards S, Zvartau M, Clarke H, Irving W, Blumhardt LD: Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:736-741.
73.
Tremlett H, van der Mei IA, Pittas F, Blizzard L, Paley G, Mesaros D, Woodbaker R, Nunez M, Dwyer T, Taylor BV, Ponsonby AL: Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology 2008;31:271-279.
74.
Sibley WA, Bamford CR, Clark K: Clinical viral infections and multiple sclerosis. Lancet 1985;1:1313-1315.
75.
Andersen O, Lygner PE, Bergström T, Andersson M, Vahlne A: Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J Neurol 1993;240:417-422.
76.
Millar JH, Allison RS, Cheeseman EA, Merrett JD: Pregnancy as a factor influencing relapse in disseminated sclerosis. Brain 1959;82:417-426.
77.
Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T: Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in multiple sclerosis group. N Engl J Med 1998;339:285-291.
78.
Vukusic S, Hutchinson M, Hours M, Moreau T, Cortinovis-Tourniaire P, Adeleine P, Confavreux C; The Pregnancy In Multiple Sclerosis Group; Pregnancy In Multiple Sclerosis Group: Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004;127:1353-1360.
79.
Nelson LM, Franklin GM, Jones MC: Risk of multiple sclerosis exacerbation during pregnancy and breast-feeding. JAMA 1988;259:3441-3443.
80.
Salemi G, Callari G, Gammino M, Battaglieri F, Cammarata E, Cuccia G, D'Amelio M, Lupo I, Ragonese P, Savettieri G: The relapse rate of multiple sclerosis changes during pregnancy: a cohort study. Acta Neurol Scand 2004;110:23-26.
81.
Hughes SE, Spelman T, Gray OM, Boz C, Trojano M, Lugaresi A, Izquierdo G, Duquette P, Girard M, Grand'Maison F, Grammond P, Oreja-Guevara C, Hupperts R, Bergamaschi R, Giuliani G, Lechner-Scott J, Barnett M, Edite Rio M, van Pesch V, Amato MP, Iuliano G, Slee M, Verheul F, Cristiano E, Fernández-Bolaños R, Poehlau D, Saladino ML, Deri N, Cabrera-Gomez J, Vella N, Herbert J, Skromne E, Savino A, Shaw C, Moore F, Vucic S, Petkovska-Boskova T, McDonnell G, Hawkins S, Kee F, Butzkueven H; MSBase study group: Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult Scler 2014;20:739-746.
82.
Korn-Lubetzki I, Kahana E, Cooper G, Abramsky O: Activity of multiple sclerosis during pregnancy and puerperium. Ann Neurol 1984;16:229-231.
83.
Bernardi S, Grasso MG, Bertollini R, Orzi F, Fieschi C: The influence of pregnancy on relapses in multiple sclerosis: a cohort study. Acta Neurol Scand 1991;84:403-406.
84.
Sadovnick AD, Eisen K, Hashimoto SA, Farquhar R, Yee IM, Hooge J, Kastrukoff L, Oger JJ, Paty DW: Pregnancy and multiple sclerosis. A prospective study. Arch Neurol 1994;51:1120-1124.
85.
Hellwig K, Haghikia A, Rockhoff M, Gold R: Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord 2012;5:247-253.
86.
Portaccio E, Ghezzi A, Hakiki B, Sturchio A, Martinelli V, Moiola L, Patti F, Mancardi GL, Solaro C, Tola MR, Pozzilli C, De Giglio L, Totaro R, Lugaresi A, De Luca G, Paolicelli D, Marrosu MG, Comi G, Trojano M, Amato MP; MS Study Group of the Italian Neurological Society: Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. J Neurol Neurosurg Psychiatry 2014;85:845-850.
87.
Hellwig K, Haghikia A, Agne H, Beste C, Gold R: Protective effect of breastfeeding in postpartum relapse rate of mothers with multiple sclerosis. Arch Neurol 2009;66:1580-1581; author reply 1581.
88.
Langer-Gould A, Huang SM, Gupta R, Leimpeter AD, Greenwood E, Albers KB, Van Den Eeden SK, Nelson LM: Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol 2009;66:958-963.
89.
Portaccio E, Ghezzi A, Hakiki B, Martinelli V, Moiola L, Patti F, La Mantia L, Mancardi GL, Solaro C, Tola MR, Pozzilli C, De Giglio L, Totaro R, Lugaresi A, De Luca G, Paolicelli D, Marrosu MG, Comi G, Trojano M, Amato MP; MS Study Group of the Italian Neurological Society: Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology 2011;77:145-150.
90.
Michel L, Foucher Y, Vukusic S, Confavreux C, de Sèze J, Brassat D, Clanet M, Clavelou P, Ouallet JC, Brochet B, Pelletier J, Labauge P, Lebrun C, Lepage E, Le Frere F, Jacq-Foucher M, Barriere P, Wiertlewski S, Laplaud DA; Club Francophone de la Sclérose En Plaques (CFSEP): Increased risk of multiple sclerosis relapse after in vitro fertilisation. J Neurol Neurosurg Psychiatry 2012;83:796-802.
91.
Laplaud DA, Leray E, Barrière P, Wiertlewski S, Moreau T: Increase in multiple sclerosis relapse rate following in vitro fertilization. Neurology 2006;66:1280-1281.
92.
Hellwig K, Schimrigk S, Beste C, Muller T, Gold R: Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis. Eur Neurol 2009;61:65-68.
93.
Correale J, Farez MF, Ysrraelit MC: Increase in multiple sclerosis activity after assisted reproduction technology. Ann Neurol 2012;72:682-694.
94.
Oikonen M, Laaksonen M, Laippala P, Oksaranta O, Lilius EM, Lindgren S, Rantio-Lehtimäki A, Anttinen A, Koski K, Erälinna JP: Ambient air quality and occurrence of multiple sclerosis relapse. Neuroepidemiology 2003;22:95-99.
95.
Heydarpour P, Amini H, Khoshkish S, Seidkhani H, Sahraian MA, Yunesian M: Potential impact of air pollution on multiple sclerosis in Tehran, Iran. Neuroepidemiology 2014;43:233-238.
96.
Miravalle A, Jensen R, Kinkel RP: Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011;68:186-191.
97.
Havla J, Gerdes LA, Meinl I, Krumbholz M, Faber H, Weber F, Pellkofer HL, Hohlfeld R, Kümpfel T: De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol 2011;258:1665-1669.
98.
Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, Anne O, Wiertlewski S, Camu W, Courtois S, Ruet A, Debouverie M, Le Page E, Casez O, Heinzlef O, Stankoff B, Bourre B, Castelnovo G, Rico A, Berger E, Camdessanche JP, Defer G, Clavelou P, Al Khedr A, Zephir H, Fromont A, Papeix C, Brochet B, Pelletier J, Lebrun C; Club Francophone de la Sclérose en Plaques Investigators: Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. JAMA Neurol 2014;71:436-441.
99.
Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L: Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP study). JAMA Neurol 2014;71:954-960.
100.
Rinaldi F, Seppi D, Calabrese M, Perini P, Gallo P: Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings. Mult Scler 2012;18:1640-1643.
101.
Jokubaitis VG, Li V, Kalincik T, Izquierdo G, Hodgkinson S, Alroughani R, Lechner-Scott J, Lugaresi A, Duquette P, Girard M, Barnett M, Grand'Maison F, Trojano M, Slee M, Giuliani G, Shaw C, Boz C, Spitaleri DL, Verheul F, Haartsen J, Liew D, Butzkueven H; MSBase Study Group: Fingolimod after natalizumab and the risk of short-term relapse. Neurology 2014;82:1204-1211.
102.
Cossburn M, Ingram G, Hirst C, Ben-Shlomo Y, Pickersgill TP, Robertson NP: Age at onset as a determinant of presenting phenotype and initial relapse recovery in multiple sclerosis. Mult Scler 2012;18:45-54.
103.
Kalincik T, Buzzard K, Jokubaitis V, Trojano M, Izquierdo G, Duquette P, Girard M, Lugaresi A, Grammond P, Grand'Maison F, Oreja-Guevara C, Boz C, Hupperts R, Petersen T, Giuliani G, Iuliano G, Lechner-Scott J, Barnett M, Bergamaschi R, Van Pesch V, Amato MP, van Munster E, Fernandez-Bolanos R, Verheul F, Fiol M, Cristiano E, Slee M, Rio ME, Spitaleri D, Alroughani R, Gray O, Saladino ML, Flechter S, Herbert J, Cabrera-Gomez JA, Vella N, Paine M, Shaw C, Moore F, Vucic S, Savino A, Singhal B, Petkovska-Boskova T, Parratt J, Sirbu CA, Rozsa C, Liew D, Butzkueven H; MSBase Study Group: Risk of relapse phenotype recurrence in multiple sclerosis. Mult Scler 2014;20:1511-1522.
104.
Fay AJ, Mowry EM, Strober J, Waubant E: Relapse severity and recovery in early pediatric multiple sclerosis. Mult Scler 2012;18:1008-1012.
105.
Hirst CL, Ingram G, Pickersgill TP, Robertson NP: Temporal evolution of remission following multiple sclerosis relapse and predictors of outcome. Mult Scler 2012;18:1152-1158.
106.
Mowry EM, Pesic M, Grimes B, Deen S, Bacchetti P, Waubant E: Demyelinating events in early multiple sclerosis have inherent severity and recovery. Neurology 2009;72:602-608.
107.
Deen S, Bacchetti P, High A, Waubant E: Predictors of the location of multiple sclerosis relapse. J Neurol Neurosurg Psychiatry 2008;79:1190-1193.
108.
Mowry EM, Deen S, Malikova I, Pelletier J, Bacchetti P, Waubant E: The onset location of multiple sclerosis predicts the location of subsequent relapses. J Neurol Neurosurg Psychiatry 2009;80:400-403.
109.
Prineas JW, Barnard RO, Revesz T, Kwon EE, Sharer L, Cho ES: Multiple sclerosis. Pathology of recurrent lesions. Brain 1993;116:681-693.
110.
Bramow S, Frischer JM, Lassmann H, Koch-Henriksen N, Lucchinetti CF, Sørensen PS, Laursen H: Demyelination versus remyelination in progressive multiple sclerosis. Brain 2010;133:2983-2998.
111.
Mowry EM, Carey RF, Blasco MR, Pelletier J, Duquette P, Villoslada P, Malikova I, Roger E, Kinkel RP, McDonald J, Bacchetti P, Waubant E: Association of multiple sclerosis susceptibility variants and early attack location in the CNS. PLoS One 2013;8:e75565.
112.
Gourraud PA, Sdika M, Khankhanian P, Henry RG, Beheshtian A, Matthews PM, Hauser SL, Oksenberg JR, Pelletier D, Baranzini SE: A genome-wide association study of brain lesion distribution in multiple sclerosis. Brain 2013;136:1012-1024.
113.
Greer JM, Csurhes PA, Muller DM, Pender MP: Correlation of blood T cell and antibody reactivity to myelin proteins with HLA type and lesion localization in multiple sclerosis. J Immunol 2008;180:6402-6410.
114.
Hutchinson M: There is no such thing as a mild MS relapse. The mild relapse is an Anglo-Saxon delusion - commentary. Mult Scler 2012;18:930-931.
115.
Confavreux C, Vukusic S, Moreau T, Adeleine P: Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-1438.
116.
Hirst C, Ingram G, Pearson O, Pickersgill T, Scolding N, Robertson N: Contribution of relapses to disability in multiple sclerosis. J Neurol 2008;255:280-287.
117.
Lublin FD, Baier M, Cutter G: Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003;61:1528-1532.
118.
Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC: The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010;133:1914-1929.
119.
Kalincik T, Vaneckova M, Tyblova M, Krasensky J, Seidl Z, Havrdova E, Horakova D: Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study. PLoS One 2012;7:e50101.
120.
Confavreux C, Vukusic S, Adeleine P: Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126:770-782.
121.
Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, Edan G: Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010;133:1900-1913.
122.
Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y; UBC Neurologists: Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 2009;73:1616-1623.
123.
Bergamaschi R, Berzuini C, Romani A, Cosi V: Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis. J Neurol Sci 2001;189:13-21.
124.
Simone IL, Carrara D, Tortorella C, Liguori M, Lepore V, Pellegrini F, Bellacosa A, Ceccarelli A, Pavone I, Livrea P: Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology 2002;59:1922-1928.
125.
Kantarci O, Siva A, Eraksoy M, Karabudak R, Sütlaş N, Ağaoğlu J, Turan F, Ozmenoğlu M, Toğrul E, Demirkiran M: Survival and predictors of disability in Turkish MS patients. Turkish multiple sclerosis study group (TUMSSG). Neurology 1998;51:765-772.
126.
Amato MP, Ponziani G, Bartolozzi ML, Siracusa G: A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. J Neurol Sci 1999;168:96-106.
127.
Leone MA, Bonissoni S, Collimedaglia L, Tesser F, Calzoni S, Stecco A, Naldi P, Monaco F: Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study. Mult Scler 2008;14:485-493.
128.
Riise T, Grønning M, Fernández O, Lauer K, Midgard R, Minderhoud JM, Nyland H, Pálffy G, Poser S, Aarli JA: Early prognostic factors for disability in multiple sclerosis, a European multicenter study. Acta Neurol Scand 1992;85:212-218.
129.
Langer-Gould A, Popat RA, Huang SM, Cobb K, Fontoura P, Gould MK, Nelson LM: Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol 2006;63:1686-1691.
130.
Baghizadeh S, Sahraian MA, Beladimoghadam N: Clinical and demographic factors affecting disease severity in patients with multiple sclerosis. Iran J Neurol 2013;12:1-8.
131.
Freund P, Wheeler-Kingshott C, Jackson J, Miller D, Thompson A, Ciccarelli O: Recovery after spinal cord relapse in multiple sclerosis is predicted by radial diffusivity. Mult Scler 2010;16:1193-1202.
132.
Mori F, Kusayanagi H, Nicoletti CG, Weiss S, Marciani MG, Centonze D: Cortical plasticity predicts recovery from relapse in multiple sclerosis. Mult Scler 2014;20:451-457.
133.
Bennetto L, Burrow J, Sakai H, Cobby J, Robertson NP, Scolding N: The relationship between relapse, impairment and disability in multiple sclerosis. Mult Scler 2011;17:1218-1224.
134.
Miller DH, Chard DT, Ciccarelli O: Clinically isolated syndromes. Lancet Neurol 2012;11:157-169.
135.
Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, Comi G, Adèr HJ, Losseff N, Valk J: Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059-2069.
136.
Tintoré M, Rovira A, Río J, Nos C, Grivé E, Téllez N, Pelayo R, Comabella M, Sastre-Garriga J, Montalban X: Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006;67:968-972.
137.
Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, Thompson AJ, Miller DH: Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808-817.
138.
O'Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, Kendall BE, Rudge P, McDonald WI, Miller DH: The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998;121:495-503.
139.
Morrissey SP, Miller DH, Kendall BE, Kingsley DP, Kelly MA, Francis DA, MacManus DG, McDonald WI: The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 1993;116:135-146.
140.
Sombekke MH, Wattjes MP, Balk LJ, Nielsen JM, Vrenken H, Uitdehaag BM, Polman CH, Barkhof F: Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis. Neurology 2013;80:69-75.
141.
Tintore M, Rovira A, Arrambide G, Mitjana R, Río J, Auger C, Nos C, Edo MC, Castilló J, Horga A, Perez-Miralles F, Huerga E, Comabella M, Sastre-Garriga J, Montalban X: Brainstem lesions in clinically isolated syndromes. Neurology 2010;75:1933-1938.
142.
Di Filippo M, Anderson VM, Altmann DR, Swanton JK, Plant GT, Thompson AJ, Miller DH: Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2010;81:204-208.
143.
Fisher E, Lee JC, Nakamura K, Rudick RA: Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008;64:255-265.
144.
Ferraro D, Simone AM, Bedin R, Galli V, Vitetta F, Federzoni L, D'Amico R, Merelli E, Nichelli PF, Sola P: Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome. J Neuroimmunol 2013;257:76-81.
145.
Jin YP, de Pedro-Cuesta J, Huang YH, Söderström M: Predicting multiple sclerosis at optic neuritis onset. Mult Scler 2003;9:135-141.
146.
Tintoré M, Rovira A, Río J, Tur C, Pelayo R, Nos C, Téllez N, Perkal H, Comabella M, Sastre-Garriga J, Montalban X: Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008;70:1079-1083.
147.
Miller DM, Weinstock-Guttman B, Béthoux F, Lee JC, Beck G, Block V, Durelli L, LaMantia L, Barnes D, Sellebjerg F, Rudick RA: A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult Scler 2000;6:267-273.
148.
Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR, et al: A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The optic neuritis study group. N Engl J Med 1992;326:581-588.
149.
Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J: Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 1998;51:529-534.
150.
Barnes D, Hughes RA, Morris RW, Wade-Jones O, Brown P, Britton T, Francis DA, Perkin GD, Rudge P, Swash M, Katifi H, Farmer S, Frankel J: Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997;349:902-906.
151.
Martinelli V, Rocca MA, Annovazzi P, Pulizzi A, Rodegher M, Martinelli Boneschi F, Scotti R, Falini A, Sormani MP, Comi G, Filippi M: A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology 2009;73:1842-1848.
152.
Alam SM, Kyriakides T, Lawden M, Newman PK: Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 1993;56:1219-1220.
153.
Oliveri RL, Valentino P, Russo C, Sibilia G, Aguglia U, Bono F, Fera F, Gambardella A, Zappia M, Pardatscher K, Quattrone A: Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology 1998;50:1833-1836.
154.
Manna SK, Aggarwal BB: Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents. J Immunol 1998;161:2873-2880.
155.
Ross AP, Ben-Zacharia A, Harris C, Smrtka J: Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone. Front Neurol 2013;4:21.
156.
Abbruzzese G, Gandolfo C, Loeb C: ‘Bolus' methylprednisolone versus ACTH in the treatment of multiple sclerosis. Ital J Neurol Sci 1983;4:169-172.
157.
Barnes MP, Bateman DE, Cleland PG, Dick DJ, Walls TJ, Newman PK, Saunders M, Tilley PJ: Intravenous methylprednisolone for multiple sclerosis in relapse. J Neurol Neurosurg Psychiatry 1985;48:157-159.
158.
Thompson AJ, Kennard C, Swash M, Summers B, Yuill GM, Shepherd DI, Roche S, Perkin GD, Loizou LA, Ferner R, et al: Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 1989;39:969-971.
159.
Ramo-Tello C, Grau-López L, Tintoré M, Rovira A, Ramió i Torrenta L, Brieva L, Cano A, Carmona O, Saiz A, Torres F, Giner P, Nos C, Massuet A, Montalbán X, Martínez-Cáceres E, Costa J: A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Mult Scler 2014;20:717-725.
160.
Filippini G, Brusaferri F, Sibley WA, Citterio A, Ciucci G, Midgard R, Candelise L: Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000;4:CD001331.
161.
Elovaara I, Apostolski S, van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, van Schaik IN, Scolding N, Soelberg Sørensen P, Udd B; EFNS: EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008;15:893-908.
162.
Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A: Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 2011;76:294-300.
163.
Berkovich R: Treatment of acute relapses in multiple sclerosis. Neurotherapeutics 2013;10:97-105.
164.
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
165.
Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
166.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators: Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-1839.
167.
He A, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Girard M, Pucci E, Iuliano G, Alroughani R, Oreja-Guevara C, Fernandez-Bolaños R, Grand'Maison F, Sola P, Spitaleri D, Granella F, Terzi M, Lechner-Scott J, Van Pesch V, Hupperts R, Sánchez-Menoyo JL, Hodgkinson S, Rozsa C, Verheul F, Butzkueven H, Kalincik T; MSBase Study Group: Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. JAMA Neurol 2015;72:405-413.
168.
Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, Duquette P, Girard M, Pucci E, Lechner-Scott J, Slee M, Fernandez-Bolanos R, Grand'Maison F, Hupperts R, Verheul F, Hodgkinson S, Oreja-Guevara C, Spitaleri D, Barnett M, Terzi M, Bergamaschi R, McCombe P, Sanchez-Menoyo J, Simo M, Csepany T, Rum G, Boz C, Havrdova E, Butzkueven H; MSBase Study Group: Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol 2015;77:425-435.
169.
Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Zipoli V, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Lepore V, Livrea P, Comi G, Amato MP; Italian Multiple Sclerosis Database Network (MSDN) Group: Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol 2009;66:513-520.
170.
Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, Di Monte E, Portaccio E, Lepore V, Livrea P, Amato MP: New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007;61:300-306.
171.
Fahrbach K, Huelin R, Martin AL, Kim E, Dastani HB, Rao S, Malhotra M: Relating relapse and t2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis. BMC Neurol 2013;13:180.
172.
Horakova D, Kalincik T, Dolezal O, Krasensky J, Vaneckova M, Seidl Z, Havrdova E: Early predictors of non-response to interferon in multiple sclerosis. Acta Neurol Scand 2012;126:390-397.
173.
Rovaris M, Comi G, Ladkani D, Wolinsky JS, Filippi M; European/Canadian Glatiramer Acetate Study Group: Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2003;24:75-81.
174.
Sormani MP, Rovaris M, Comi G, Filippi M: A composite score to predict short-term disease activity in patients with relapsing-remitting MS. Neurology 2007;69:1230-1235.
175.
Burman J, Iacobaeus E, Svenningsson A, Lycke J, Gunnarsson M, Nilsson P, Vrethem M, Fredrikson S, Martin C, Sandstedt A, Uggla B, Lenhoff S, Johansson JE, Isaksson C, Hägglund H, Carlson K, Fagius J: Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg Psychiatry 2014;85:1116-1121.
176.
Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, Oyama Y, Russell EJ, Stern J, Muraro P, Rose J, Testori A, Bucha J, Jovanovic B, Milanetti F, Storek J, Voltarelli JC, Burns WH: Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009;8:244-253.
177.
Mancardi GL, Sormani MP, Di Gioia M, Vuolo L, Gualandi F, Amato MP, Capello E, Currò D, Uccelli A, Bertolotto A, Gasperini C, Lugaresi A, Merelli E, Meucci G, Motti L, Tola MR, Scarpini E, Repice AM, Massacesi L, Saccardi R; Italian BMT Study Group: Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Mult Scler 2012;18:835-842.
178.
Ross AP, Halper J, Harris CJ: Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective. Int J MS Care 2012;14:148-159.
179.
Perrin Ross A, Williamson A, Smrtka J, Flemming Tracy T, Saunders C, Easterling C, Niewoehner J, Mutschler N: Assessing relapse in multiple sclerosis questionnaire: results of a pilot study. Mult Scler Int 2013;2013:470476.
180.
Oleen-Burkey M, Castelli-Haley J, Lage MJ, Johnson KP: Burden of a multiple sclerosis relapse: the patient's perspective. Patient 2012;5:57-69.
181.
Healy BC, Degano IR, Schreck A, Rintell D, Weiner H, Chitnis T, Glanz BI: The impact of a recent relapse on patient-reported outcomes in subjects with multiple sclerosis. Qual Life Res 2012;21:1677-1684.
182.
Nickerson M, Marrie RA: The multiple sclerosis relapse experience: patient-reported outcomes from the north American research committee on multiple sclerosis (NARCOMS) registry. BMC Neurol 2013;13:119.
183.
Di Pauli F, Reindl M, Ehling R, Schautzer F, Gneiss C, Lutterotti A, O'Reilly E, Munger K, Deisenhammer F, Ascherio A, Berger T: Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. Mult Scler 2008;14:1026-1030.
184.
Brown RF, Tennant CC, Sharrock M, Hodgkinson S, Dunn SM, Pollard JD: Relationship between stress and relapse in multiple sclerosis: Part I. Important features. Mult Scler 2006;12:453-464.
185.
Buljevac D, Hop WC, Reedeker W, Janssens AC, van der Meché FG, van Doorn PA, Hintzen RQ: Self reported stressful life events and exacerbations in multiple sclerosis: prospective study. BMJ 2003;327:646.
186.
Oikonen M, Laaksonen M, Aalto V, Ilonen J, Salonen R, Erälinna JP, Panelius M, Salmi A: Temporal relationship between environmental influenza a and epstein-barr viral infections and high multiple sclerosis relapse occurrence. Mult Scler 2011;17:672-680.
187.
Roullet E, Verdier-Taillefer MH, Amarenco P, Gharbi G, Alperovitch A, Marteau R: Pregnancy and multiple sclerosis: a longitudinal study of 125 remittent patients. J Neurol Neurosurg Psychiatry 1993;56:1062-1065.
188.
Giorgio A, Battaglini M, Rocca MA, De Leucio A, Absinta M, van Schijndel R, Rovira A, Tintoré M, Chard D, Ciccarelli O, Enzinger C, Gasperini C, Frederiksen J, Filippi M, Barkhof F, De Stefano N; MAGNIMS Study Group: Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. Neurology 2013;80:234-241.
189.
Ruet A, Arrambide G, Brochet B, Auger C, Simon E, Rovira A, Montalban X, Tintoré M: Early predictors of multiple sclerosis after a typical clinically isolated syndrome. Mult Scler 2014;20:1721-1726.
190.
Mitjana R, Tintoré M, Rocca MA, Auger C, Barkhof F, Filippi M, Polman C, Fazekas F, Huerga E, Montalban X, Rovira A: Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes. Mult Scler 2014;20:1471-1477.
191.
Hartung HP, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, Montalbán X, Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group: Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology 2011;77:835-843.
192.
Comi G, Martinelli V, Rodegher M, Moiola L, Leocani L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Preziosa P, Ravnborg M, Rieckmann P, Rocca MA, Wynn D, Young C, Filippi M: Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler 2013;19:1074-1083.
193.
Kinkel RP, Dontchev M, Kollman C, Skaramagas TT, O'Connor PW, Simon JH; Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance Investigators: Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the controlled high-risk avonex multiple sclerosis prevention study in ongoing neurological surveillance. Arch Neurol 2012;69:183-190.
194.
Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW; TOPIC Study Group: Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:977-986.
195.
Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, Smith S, Comi G: Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004;364:1489-1496.
196.
Runia TF, Jafari N, Siepman DA, Hintzen RQ: Fatigue at time of CIS is an independent predictor of a subsequent diagnosis of multiple sclerosis. J Neurol Neurosurg Psychiatry 2014;86:543-546.
197.
Chard DT, Dalton CM, Swanton J, Fisniku LK, Miszkiel KA, Thompson AJ, Plant GT, Miller DH: MRI only conversion to multiple sclerosis following a clinically isolated syndrome. J Neurol Neurosurg Psychiatry 2011;82:176-179.
198.
Patrucco L, Rojas JI, Cristiano E: Assessing the value of spinal cord lesions in predicting development of multiple sclerosis in patients with clinically isolated syndromes. J Neurol 2012;259:1317-1320.
199.
Rovaris M, Agosta F, Sormani MP, Inglese M, Martinelli V, Comi G, Filippi M: Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study. Brain 2003;126:2323-2332.
200.
Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH: A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158-164.
201.
Dalton CM, Chard DT, Davies GR, Miszkiel KA, Altmann DR, Fernando K, Plant GT, Thompson AJ, Miller DH: Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004;127:1101-1107.
202.
Dalton CM, Brex PA, Jenkins R, Fox NC, Miszkiel KA, Crum WR, O'Riordan JI, Plant GT, Thompson AJ, Miller DH: Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;73:141-147.
203.
Villar LM, Espiño M, Roldán E, Marín N, Costa-Frossard L, Muriel A, Alvarez-Cermeño JC: Increased peripheral blood CD5+ B cells predict earlier conversion to MS in high-risk clinically isolated syndromes. Mult Scler 2011;17:690-694.
204.
Liu Y, Duan Y, Yu C, Qin W, Chen H, Dong H, Ye J, Butzkueven H, Li K: Clinical isolated syndrome: a 3-year follow-up study in China. Clin Neurol Neurosurg 2011;113:658-660.
205.
Magraner MJ, Bosca I, Simó-Castelló M, García-Martí G, Alberich-Bayarri A, Coret F, Alvarez-Cermeño JC, Martí-Bonmatí L, Villar LM, Casanova B: Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. Neuroradiology 2012;54:5-12.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.